Baron & Budd Attorney and Shareholder Burton LeBlanc to Speak on Opioid Epidemic at American Association for Justice
BATON ROUGE, La. – November 17, 2017 – The national law firm of Baron & Budd is pleased to...READ MORE
Sanofi-Aventis, the manufacturer of the chemotherapy drug Taxotere, has made billions of dollars off of the medication. However, plaintiffs in lawsuits across the country allege that Sanofi knew that Taxotere causes permanent hair loss yet failed to warn patients. If you are considering legal action against Sanofi, Baron & Budd may be able to help.
Whenever someone undergoes chemotherapy treatment, hair loss is to be expected. But, in the majority of cases, hair grows back once chemo treatments are complete. Unfortunately, that doesn’t seem to be the case with Taxotere.
Thousands of women who took Taxotere to treat breast cancer have suffered permanent hair loss. Even worse, they could have taken a drug that is similar to Taxotere, known as Taxol, which is believed to be just as effective – without causing permanent baldness.
In some severe cases, women who took Taxotere have suffered from alopecia (hair loss) for 10 years or longer. This can cause a crushing blow to self-esteem and can lead to depression and a diminished quality of life.
For many of these women, the advantages of taking Taxotere have been far outweighed by the disadvantages. Taxotere is popular because patients only have to undergo treatments every three weeks, compared to other drugs that require weekly treatments. However, if patients knew that this “convenience” could result in permanent baldness, many may have chosen the weekly treatments of Taxol.